Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell
Open accessThe DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Abstract
Insulin resistance and type 2 diabetes mellitus are associated with impaired postprandial secretion of glucagon-like peptide-1 (GLP-1), a potent insulinotropic hormone. The direct effects of insulin and insulin resistance on the L cell are unknown. We therefore hypothesized that the L cell is responsive to insulin and that insulin resistance impairs GLP-1 secretion. The effects of insulin and insulin resistance were examined in well-characterized L cell models: murine GLUTag, human NCI-H716, and fetal rat intestinal cells. MKR mice, a model of chronic hyperinsulinemia, were used to assess the function of the L cell in vivo. In all cells, insulin activated the phosphatidylinositol 3 kinase-Akt and MAPK kinase (MEK)-ERK1/2 pathways and stimulated GLP-1 secretion by up to 275 ± 58%. Insulin resistance was induced by 24 h pretreatment with 10−7m insulin, causing a marked reduction in activation of Akt and ERK1/2. Furthermore, both insulin-induced GLP-1 release and secretion in response to glucose-dependent insulinotropic peptide and phorbol-12-myristate-13-acetate were significantly attenuated. Whereas inhibition of phosphatidylinositol 3 kinase with LY294002 potentiated insulin-induced GLP-1 release, secretion was abrogated by inhibiting the MEK-ERK1/2 pathway with PD98059 or by overexpression of a kinase-dead MEK1-ERK2 fusion protein. Compared with controls, MKR mice were insulin resistant and displayed significantly higher fasting plasma insulin levels. Furthermore, they had significantly higher basal GLP-1 levels but displayed impaired GLP-1 secretion after an oral glucose challenge. These findings indicate that the intestinal L cell is responsive to insulin and that insulin resistance in vitro and in vivo is associated with impaired GLP-1 secretion. Insulin is a novel secretagogue of the incretin hormone, glucagon-like peptide-1 (GLP-1), and L cell insulin resistance impairs heterologous secretagogue-induced GLP-1 secretion in vitro and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, GLP-1 and GIP mediate insulin secretion and concomitantly, insulin modulates GIP212 and GLP-1 release; the latter ocurring through the PI3K/Akt- and mitogen-activated protein kinase kinase (MAPKK or MEK)/ERK1/2 pathway.213”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [213]
Citations
Cites
1 retracted
Bi-directional Regulation of Brown Fat Adipogenesis by the Insulin Receptor
Entingh, A. J., Taniguchi, C. M., & Kahn, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303056200 · Cited by 59 · cited 2×
“Identification of mouse and human insulin receptor transcripts was based on primers and conditions reported to generate PCR products of 500 or 600 (isoform A)/636 (isoform B) bp, respectively (36, 37).”
MethodRetractedThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 6×
“org Endocrinology, February 2009, 150(2):580–591”
BackgroundInfluentialVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“Given the demonstrated importance of endogenous GLP-1 release to the maintenance of normal insulin secretion and glucose homeostasis (47, 48), it is therefore somewhat paradoxical that postprandial GLP-1 release is decreased in subjects with type 2 diabetes and insulin resistance, independent of obesity (18–24).”
BackgroundSelf-citationGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534 · cited 1×
“Interestingly, although GIP and PMA stimulate GLP-1 secretion through the activation of protein kinase A and protein kinase C isoenzymes, respectively (9, 70), recent studies demonstrated that these secretagogues can also activate the MEK-ERK1/2 pathway in other cell models (71, 72).”
BackgroundVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202766200 · Cited by 500 · cited 1×
“Identification of mouse and human insulin receptor transcripts was based on primers and conditions reported to generate PCR products of 500 or 600 (isoform A)/636 (isoform B) bp, respectively (36, 37).”
Method
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The Impact of Food Bioactives on Health
(2015) · Springer eBooks · doi:10.1007/978-3-319-16104-4 · Cited by 805
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
“…other tissues and organs, including the stomach by delaying gastric emptying, the heart by exerting cardioprotective effects, and adipose tissue and skeletal muscle by improving glucose uptake, and it also acts centrally on neurons in the hypothalamus, inducing a feeling of satiety [99–101].”
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
“As a parallel to the insulin resistance-associated hyperinsulinaemic state in the early stages of type 2 diabetes (followed by insulin hyposecretion in the later stages), we hypothesise that compensatory L cell secretion of GLP-1 may exist in the early stages of type 2 diabetes, followed by L cell ‘exhaustion’ when th…”
Psichas, A., Reimann, F., & Gribble, F. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76309 · Cited by 243
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Balakumar, M., Prabhu, D., Sathishkumar, C., Prabu, P., Rokana, N., Kumar, R., Raghavan, S., Soundarajan, A., Grover, S., Batish, V. K., et al. (2018) · European Journal of Nutrition · doi:10.1007/s00394-016-1317-7 · Cited by 187
Signaling mechanisms of glucose-induced F-actin remodeling in pancreatic islet β cells
Kalwat, M. A., & Thurmond, D. C. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.73 · Cited by 158
Petriello, M. C., Hoffman, J. B., Vsevolozhskaya, O. A., Morris, A. J., & Hennig, B. (2018) · Environmental Pollution · doi:10.1016/j.envpol.2018.07.039 · Cited by 154
“Furthermore, GLP-1 and GIP are both insulinotropic incretins, but there is evidence that hyperinsulinemia and insulin resistance can cause impairments in GLP-1 secretion from intestinal L cells (Lim et al. 2009).”
BackgroundInflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“Conversely, L cells are responsive to insulin and insulin resistance is associated with impaired GLP-1 secretion in vitro and in vivo (48).”
BackgroundCircadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell
Gil‐Lozano, M., Mingomataj, E., Wu, W. K., Ridout, S. A., & Brubaker, P. L. (2014) · Diabetes · doi:10.2337/db13-1501 · Cited by 145
“Furthermore, we also found that mGLUTag cell responses to GIP and insulin, which are known to stimulate GLP-1 secretion by activating cAMP and Erk1/2 signaling, respectively (36,37), showed a similar pattern, indicating that the daily variation in the L-cell responsiveness to stimulus is independent of the signaling p…”
BackgroundSelf-citationMinireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
“Notwithstanding, studies conducted in vitro in human and murine L cells, and in vivo in mice, have demonstrated that insulin resistance at the level of the intestinal L cell can impair secretagogue-induced release of GLP-1 (46), while reduced insulin sensitivity in normal individuals is linked to lower levels of GLP-1…”
Self-citationShao, W., Wang, D., Chiang, Y., Ip, W., Zhu, L., Xu, F., Columbus, J., Belsham, D. D., Irwin, D. M., Zhang, H., et al. (2012) · Diabetes · doi:10.2337/db12-0365 · Cited by 124
“In the insulin-resistant MKR mouse model, although nutrient-stimulated GLP-1 secretion was lower than in the control mice, basal plasma GLP-1 levels were higher than levels in the wild-type littermates, making the postprandial plasma GLP-1 levels in the two groups of mice comparable (45).”
BackgroundTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110
“Insulin resistance at the level of the intestinal L-cell can impair secretagogue-induced release of GLP-1, whereas reduced insulin sensitivity in normal individuals is linked to lower levels of GLP-1 (63,64).”
BackgroundGhrelin Is a Novel Regulator of GLP-1 Secretion
Gagnon, J., Baggio, L. L., Drucker, D. J., & Brubaker, P. L. (2014) · Diabetes · doi:10.2337/db14-1176 · Cited by 130
“The satiety factor, leptin, also stimulates GLP-1 release by rodent and human L-cells (11), as does the metabolic hormone, insulin (12).”
BackgroundInfluentialSelf-citationGlucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function
Brubaker, P. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170055 · Cited by 137
Self-citationThe incretin hormone GLP‐1 and mechanisms underlying its secretion: 肠促胰岛素激素GLP‐1及其潜在的分泌机制
Tian, L., & Jin, T. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12439 · Cited by 94
Stimulation of incretin secreting cells
Pais, R., Gribble, F. M., & Reimann, F. M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815618177 · Cited by 115
Farokhnia, M., McDiarmid, G. R., Newmeyer, M. N., Munjal, V., Abulseoud, O. A., Huestis, M. A., & Leggio, L. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0756-3 · Cited by 104
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
“…peptide (GIP) (Roberge & Brubaker, 1993), and gastrin-releasing peptide (GRP) (Persson et al., 2000), increase GLP-1 release, while insulin (Lim et al., 2009) and somatostatin (Moss et al., 2012) provide negative feedback, demonstrating that GLP-1 release from the gut is under multiple…”
BackgroundInsulin and Norepinephrine Regulate Ghrelin Secretion from a Rat Primary Stomach Cell Culture
Gagnon, J., & Anini, Y. (2012) · Endocrinology · doi:10.1210/en.2012-1040 · Cited by 91
“The inhibitory effect of insulin was blocked by inhibiting phospho-inositol-3 kinase and AKT but not MAPK.”
BackgroundMethodInfluentialKato, M., Tani, T., Terahara, N., & Tsuda, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126157 · Cited by 91
Takikawa, M., Kurimoto, Y., & Tsuda, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.092 · Cited by 81
Xu, E., Schwab, M. G., & Marette, A. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9282-4 · Cited by 85
“Finally, insulin can regulate its own expression and secretion by an autocrine action in the pancreatic β-cells [48, 49] and by promoting GLP-1 secretion from the intestinal L-cells [50].”
BackgroundPharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound
Le, J., Ji, H., Zhou, X., Wei, X., Chen, Y., Fu, Y., Ma, Y., Han, Q.-Q., Sun, Y., Gao, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714586 · Cited by 88
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Molecular mechanisms underlying nutrient detection by incretin-secreting cells
Reimann, F. (2009) · International Dairy Journal · doi:10.1016/j.idairyj.2009.11.014 · Cited by 61
Tunduguru, R., Chiu, T. T., Ramalingam, L., Elmendorf, J. S., Klip, A., & Thurmond, D. C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.033 · Cited by 59
Stinson, S. E., Jonsson, A. E., Lund, M. A. V., Frithioff‐Bøjsøe, C., Holm, L. A., Pedersen, O. B., Ängquist, L. H., Sørensen, T. I. A., Holst, J. J., Christiansen, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab098 · Cited by 66
Chylomicrons stimulate incretin secretion in mouse and human cells
Psichas, A., Larraufie, P., Goldspink, D. A., Gribble, F. M., & Reimann, F. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4420-2 · Cited by 58
“Although ERK signalling has been implicated in the GLP-1 secretory response to a variety of stimuli [26, 27], how ERK couples to secretion remains to be determined.”
BackgroundMethodHyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by TargetingMafb
Zhu, M., Wei, Y., Geißler, C., Abschlag, K., Corbalán-Campos, J., Hristov, M., Möllmann, J., Lehrke, M., Karshovska, E., & Schober, A. (2017) · Diabetes · doi:10.2337/db17-0313 · Cited by 62
“Insulin can trigger GLP-1 secretion from L cells, and plasma GLP-1 levels are elevated in hyperinsulinemic mice (53).”
BackgroundZhang, G., Hasek, L. Y., Lee, B.-H., & Hamaker, B. R. (2015) · Food & Function · doi:10.1039/c4fo00803k · Cited by 58
The role of insulin signaling in the development of β-cell dysfunction and diabetes
Wang, Q., & Jin, T. (2009) · Islets · doi:10.4161/isl.1.2.9263 · Cited by 64
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 59
“Thus, it has recently been claimed that human L-cells express insulin receptors and secrete GLP-1 in response to insulin in vitro and that a condition of insulin resistance is associated with a loss of this function [50].”
Chronic Exposure to TNFα Impairs Secretion of Glucagon-Like Peptide-1
Gagnon, J., Sauvé, M., Zhao, W. T., Stacey, H. M., Wiber, S. C., Bolz, S. S., & Brubaker, P. L. (2015) · Endocrinology · doi:10.1210/en.2015-1361 · Cited by 58
Self-citationFlock, G. B., Cao, X., Maziarz, M., & Drucker, D. J. (2012) · Diabetes · doi:10.2337/db12-0601 · Cited by 59
Zatorski, H., Sałaga, M., & Fichna, J. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01698-z · Cited by 56
Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.
Buckley, M. M., O’Mahony, S. M., & O’Malley, D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8846 · Cited by 73
Opposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors
Engelstoft, M. S., & Schwartz, T. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.07.001 · Cited by 61
Qin, W., Ying, W., Hamaker, B., & Zhang, G. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12808 · Cited by 48
The regulation of function, growth and survival of GLP-1-producing L-cells
Kuhre, R. E., Holst, J. J., & Krizhanovskii, C. (2015) · Clinical Science · doi:10.1042/cs20150154 · Cited by 54
Dusaulcy, R., Handgraaf, S., Skarupelova, S., Visentin, F., Vesin, C., Heddad-Masson, M., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2016) · Endocrinology · doi:10.1210/en.2016-1433 · Cited by 56
Progressive change of intra‐islet GLP‐1 production during diabetes development
O’Malley, T. J., Fava, G. E., Zhang, Y., Fonseca, V. A., & Wu, H. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2534 · Cited by 50
“Indeed, elevated glucose concentration has been shown to be a potent stimulus for GLP-1 production in both L-cells and islet cultures [2,21,28,30].”
BackgroundInfluentialSangle, G. V., Lauffer, L. M., Grieco, A. J., Trivedi, S., Iakoubov, R., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1732 · Cited by 53
“Proteins of interest were detected with antibodies targeted against phospho-Akt (Ser473), Akt, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2 (1:1000; Cell Signaling, Danvers, MA), and actin (1:5000; Sigma-Aldrich Canada), as previously described (29, 30).”
BackgroundMethodSelf-citationGhrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 51
Self-citationLim, G. E., Xu, M., Sun, J., Jin, T., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2009-0508 · Cited by 49
Self-citationAndres, S. F., Santoro, M. A., Mah, A. T., Keku, J., Bortvedt, A., Blue, R. E., & Lund, P. K. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00287.2014 · Cited by 49
Wheeler, S. E., Stacey, H. M., Nahaei, Y., Hale, S. J., Hardy, A. B., Reimann, F. M., Gribble, F. M., Larraufie, P., Gaisano, H. Y., & Brubaker, P. L. (2017) · Diabetes · doi:10.2337/db16-1403 · Cited by 48
“5 or 3g/kg permits detection of bioactive GLP-1 release in mice (36); and IPGTT: 3 g/kg glucose, as determined in pilot studies to match the glycemic response observed in the OGTT, data not shown) and tail-vein blood collection.”
MethodSelf-citationHiggins, V., Asgari, S., Hamilton, J. K., Wolska, A. T., Remaley, A. T., Hartmann, B., Holst, J. J., & Adeli, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz261 · Cited by 50
Cremonini, E., Daveri, E., Mastaloudis, A., & Oteiza, P. I. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab029 · Cited by 47
“The medium was collected and secreted GLP-1 was assessed using an ELISA kit specific for total GLP-1 (1-36), (7-36), and (9-36) amides (Crystal Chem Inc.”
BackgroundMethodChiang, Y.-T. A., Shao, W., Xu, X. X., Chernoff, J., & Jin, T. (2012) · Endocrinology · doi:10.1210/en.2012-1781 · Cited by 43
“Furthermore, Pak1 plays a role in the secretion of metabolic hormones, including insulin and GLP-1 (18, 26, 47).”
BackgroundGagnon, J., & Anini, Y. (2013) · Endocrinology · doi:10.1210/en.2012-1994 · Cited by 49
Essential Role of Syntaxin-Binding Protein-1 in the Regulation of Glucagon-Like Peptide-1 Secretion
Campbell, J. R., Martchenko, A., Sweeney, M. E., Maalouf, M. F., Psichas, A., Gribble, F. M., Reimann, F. M., & Brubaker, P. L. (2020) · Endocrinology · doi:10.1210/endocr/bqaa039 · Cited by 42
“An oral glucose tolerance test (OGTT) was performed 7 to 9 days following treatment with tamoxifen or vehicle (6, 24, 27).”
MethodSelf-citationGLP-2 and leptin are associated with hyperinsulinemia in non-obese female migraineurs
Bernecker, C., Pailer, S., Kieslinger, P., Horejsi, R., Möller, R., Lechner, A., Wallner-Blazek, M., Weiss, S., Fazekas, F., Truschnig-Wilders, M., et al. (2010) · Cephalalgia · doi:10.1177/0333102410364674 · Cited by 40
Liu, Y., Si, M., Lü, W., Zhang, L., Zhou, C., Deng, S., & Wu, H. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.03.014 · Cited by 40
The Role of Gasotransmitters in Gut Peptide Actions
Verbeure, W., van Goor, H., Mori, H., van Beek, A. P., Tack, J. F., & van Dijk, P. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720703 · Cited by 42
Harada, N., Hamasaki, A., Yamane, S., Muraoka, A., Joo, E., Fujita, K., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00078.x · Cited by 37
Li, S. K., Zhu, D. Y., Gaisano, H. Y., & Brubaker, P. L. (2013) · Diabetologia · doi:10.1007/s00125-013-3143-2 · Cited by 39
“VAMP1/2/3 immunoreactivity was identified in primary murine L cells by immunofluorescence of formalin-fixed, paraffin-embedded mouse ileal sections, as described [26].”
BackgroundSelf-citationSalinari, S., BERTUZZI, A., & Mingrone, G. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00451.2010 · Cited by 43
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
The effect of dipeptidyl peptidase‐IV inhibition on bone in a mouse model of type 2 diabetes
Gallagher, E. J., Sun, H., Kornhauser, C., Tobin‐Hess, A., Epstein, S., Yakar, S., & LeRoith, D. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2466 · Cited by 34
Self-citationGlucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects
Krizhanovskii, C., Fransson, L., Wolbert, P., & Ortsäter, H. (2015) · Clinical Science · doi:10.1042/cs20140719 · Cited by 37
Ywhaz/14-3-3ζ Deletion Improves Glucose Tolerance Through a GLP-1-Dependent Mechanism
Lim, G. E., Piske, M., Lulo, J. E., Ramshaw, H. S., Lopez, A. F., & Johnson, J. D. (2016) · Endocrinology · doi:10.1210/en.2016-1016 · Cited by 34
Self-citationYang, W., Zhang, C., Ji, W.-Y., Zhao, L.-L., Yang, F.-Y., Zhang, L., & Cao, X. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500113 · Cited by 38
Cen, H. H., Hussein, B., Botezelli, J. D., Wang, S., Zhang, J. A., Noursadeghi, N., Jessen, N., Rodrigues, B., Timmons, J. A., & Johnson, J. D. (2021) · The FASEB Journal · doi:10.1096/fj.202100497rr · Cited by 48
Paschetta, E., Hvalryg, M., & Musso, G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00897.x · Cited by 37
“investigated a possible dys-regulation of incretin secretion or degradation by comparing incretin profiles in healthy lean or obese men after ingestion of a mixed meal or oral glucose; in obese subjects, GLP-1 but not GIP secretion is lower after meal ingestion and oral glucose, whereas GIP but not GLP-1 metabolism is…”
BackgroundFilippello, A., Urbano, F., Mauro, S. D., Scamporrino, A., Pino, A. D., Scicali, R., Rabuazzo, A. M., Purrello, F., & Piro, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123791 · Cited by 32
“Previous studies that already addressed this issue, found that insulin resistance impaired GLP-1 secretion form GLUTag cells by down-regulating the MAPK intracellular pathway [8].”
BackgroundMethodInfluentialWang, J., Liu, S., Ma, J., & Piao, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.706396 · Cited by 37
Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
Unger, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0404-x · Cited by 30
Casanova‐Martí, À., Serrano, J., Blay, M., Terra, X., Ardèvol, A., & Pinent, M. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1321347 · Cited by 33
Yang, C., Zhang, T., Tian, Q., Cheng, Y., Gebeyew, K., Liu, G., Tan, Z., & He, Z. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.795081 · Cited by 32
Chang, E., Kim, L., Choi, J. M., Park, S. E., Rhee, E., Lee, W., Oh, K.-W., Park, S., Park, D. I., & Park, C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.02.001 · Cited by 30
“GLP-1 secretion is mediated in an MEK/ERKdependent manner [27,49].”
BackgroundGlucagon‐like peptide‐1: The missing link in the metabolic clock?
Brubaker, P. L., & Gil‐Lozano, M. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12477 · Cited by 39
Self-citationCurcumin induces secretion of glucagon-like peptide-1 through an oxidation-dependent mechanism
Alli-Oluwafuyi, A.-M., Luis, P. B., Nakashima, F., Giménez-Bastida, J. A., Presley, S. H., Duvernay, M. T., Iwalewa, E. O., & Schneider, C. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.013 · Cited by 28
“Extracellular regulated kinase (ERK) is downstream of PKC and CaMKII and involved in GLP-secretion (29,30).”
BackgroundMechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 33
“Leptin and insulin are both GLP-1 secretagogues, and resistance to either hormone is known to inhibit GLP-1 secretion (Anini and Brubaker, 2003, Lim et al. 2009).”
BackgroundLaminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
Yang, L., Wang, L., Zhu, C., Wu, J., Yuan, Y., Yu, L., Xu, Y., Xu, J., Wang, T., Liao, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19957 · Cited by 28
“To date, various signaling pathways, which include Wnt [48], mTOR [49], and MEK-ERK [50], are involved in GLP-1 synthesis or secretion.”
Evidence for paracrine/autocrine regulation of GLP-1-producing cells
Krizhanovskii, C., Zhang, Q., Holst, J. J., Nyström, T., & Sjöholm, Å. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00227.2013 · Cited by 31
Gastrointestinal capacity, gut hormones and appetite change during rat pregnancy and lactation
Johnson, M. L., Saffrey, M. J., & Taylor, V. (2019) · Reproduction · doi:10.1530/rep-18-0414 · Cited by 30
“565 GLP-1 is a satiety hormone and decreases in insulin-resistant states (Toft-Nielsen et 566 al., 2001, Muscelli et al., 2008, Lim et al., 2009).”
BackgroundGlucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
Larsen, M. P., & Torekov, S. S. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7583506 · Cited by 28
O’Malley, D. (2018) · Experimental Physiology · doi:10.1113/ep087443 · Cited by 30
Ghrelin regulates GLP-1 production through mTOR signaling in L cells
Xu, G., Hong, X., Tang, H. W., Jiang, S., Liu, F., Shen, Z., Li, Z., & Zhang, W. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.016 · Cited by 25
“GIP (Damholt et al., 1998), leptin (Anini and Brubaker, 2003) and insulin (Lim et al., 2009) enhance GLP-1 secretion.”
BackgroundZheng, J., Xiao, K., Chen, L., Wu, C., Hu, X., Zeng, T., Chen, X.-Q., Li, W., Deng, X., Li, H., et al. (2017) · Nutrition · doi:10.1016/j.nut.2017.01.002 · Cited by 24
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2014) · Mediators of Inflammation · doi:10.1155/2014/923120 · Cited by 24
INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells
Ang, S. Y., Evans, B. A., Poole, D. P., Bron, R., DiCello, J. J., Bathgate, R. A. D., Kočan, M., Hutchinson, D. S., & Summers, R. J. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0152 · Cited by 28
“In contrast, NCI-H716 cells, a commonly used human model of enteroendocrine L-cells (Reimer et al. 2001, Jang et al. 2007, Lauffer et al. 2009, Lim et al. 2009) originally derived from ascites fluid of a patient with caecal adenocarcinoma (Park et al. 1987, Gagnon & Brubaker 2015), expressed…”
BackgroundYuan, X., Ni, H., Chen, X., Feng, X., Wu, Q., & Chen, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27343 · Cited by 27
“It has been reported that GLP‐1 plays an important role in maintaining glucose homeostasis and the balance of intestinal flora.(12,13) Alternation of intestinal flora could be one of the factors responsible for the development of DM.”
BackgroundAnti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish
Bertelli, P. R., Mocelin, R., Marcon, M., Sachett, A., Gomez, R., Rosa, A. R., Herrmann, A. P., & Piato, Â. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110388 · Cited by 26
Physiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
“…(studies on cell lines suggest stimulation through the extracellular signal-related kinase 1/2 (ERK1/2) [83], insulin (studies on cell lines suggest a role for phosphatidylinositol 3 kinase-Akt and MAPK kinase (MEK)-ERK1/2 pathways [84], and glucocorticoid (reduced GLP-1 secretion in rodents) [85].”
BackgroundThe Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell
Brubaker, P. L. (2022) · Endocrinology · doi:10.1210/endocr/bqac159 · Cited by 23
Self-citationChiang, Y.-T. A., Ip, W., Shao, W., Song, Z., Chernoff, J., & Jin, T. (2014) · Endocrinology · doi:10.1210/en.2013-1743 · Cited by 22
O’Malley, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00272.2016 · Cited by 24
Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice
Rubio, C., Puerto, M., García‐Rodríguez, J. J., Lu, V. B., García‐Martinez, I., Alén, R., Sanmartín-Salinas, P., Toledo-Lobo, M. V., Sáiz, J., Rupérez, F. J., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.018 · Cited by 23
The intestine and the microbiota in maternal glucose homeostasis during pregnancy
Yeo, E., Brubaker, P. L., & Sloboda, D. M. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0354 · Cited by 22
Self-citationYoshihara, M., Akasaka, H., Ohnishi, H., Miki, T., Furukawa, T., Yuda, S., Saitoh, S., & Miura, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067578 · Cited by 17
Glucolipotoxicity and GLP-1 secretion
Hong, J.-H., Kim, D., & Lee, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001905 · Cited by 17
GLP-1 Secretion in Response to Oral and Luminal Palatinose (Isomaltulose) in Rats
Hira, T., Muramatsu, M., OKUNO, M., & Hara, H. (2011) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.57.30 · Cited by 18
Harada, K., Kitaguchi, T., & Tsuboi, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.151 · Cited by 16
Kindel, T. L., Yang, Q., Yoder, S. M., & Tso, P. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90506.2008 · Cited by 19
“GLP-1-(1-36, 1-37, 9-36, 9-37), as well as glucagon or GLP-2.”
BackgroundInfluentialReview on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
Colonic L-cell impairment in aged subjects with type 2 diabetes leads to diminished GLP-1 production
Wang, Q., Zhang, W., Zhao, Y., Chen, H.-L., Liu, Q., Wang, Z., Zeng, L.-T., Li, J., Chen, S., Wei, L., et al. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102907 · Cited by 15
Metadata
- Authors
- Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L.
- Affiliations
- University of Toronto (CA)
- Icahn School of Medicine at Mount Sinai (US)
- University of Chicago (US)
- Corresponding author
- Brubaker, Patricia L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-02-01
- Volume
- 150
- Issue
- 2
- Pages
- 580-591
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC5393261
- OpenAlex
- W2010671489
- Cited by
- 200
- References
- 75
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 5 · 2021: 25 · 2020: 8 · 2019: 12 · 2018: 10 · 2017: 14 · 2016: 12 · 2015: 17 · 2014: 11 · 2013: 14 · 2012: 12
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK050610, R01DK055267)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- insulin, glucagon-like peptide-1, enteroendocrine L cells, insulin resistance, type 2 diabetes, phosphatidylinositol 3-kinase, Akt signaling, MEK/ERK1/2 pathway, GLP-1 secretion, hyperinsulinemia, glucose-dependent insulinotropic polypeptide, intestinal hormone secretion
- MeSH terms
- Animals, Cells, Cultured, Female, Humans, Insulin, Insulin Resistance, Insulin-Like Growth Factor I, Male, Pregnancy, Receptor, Insulin, Signal Transduction, Rats, Wistar, Receptor, IGF Type 1, Mice, Knockout, Enteroendocrine Cells, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.